Advising the court - appointed liquidators of a distributor
of pharmaceutical products concerning the alleged fraudulent misappropriation of significant sums of money by former directors.
Not exact matches
The Fresenius probe follows
concerns raised in February by the Federal Trade Commission regarding greater scrutiny
of complex inhalant and injectable
products involved in big
pharmaceutical takeovers.
These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going
concern, our ability to develop and market diagnostic
products, the level
of third party reimbursement for our
products, risks related to preclinical and clinical development
of pharmaceutical products, including the identification
of compounds and the completion
of clinical trials, our ability to form collaborative relationships, the effect
of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our
products, dependence on collaborative relationships, the effect
of competitive
products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
These risks and uncertainties include, among others, those relating to our ability to obtain sufficient financing to continue as a going
concern, the outcome
of the review
of the continued listing
of our common stock on The Nasdaq Stock Market, our ability to develop and market diagnostic
products, the level
of third party reimbursement for our
products, risks related to preclinical and clinical development
of pharmaceutical products, including the identification
of compounds and the completion
of clinical trials, our ability to form collaborative relationships, the effect
of government regulation and the regulatory approval processes, market acceptance, our ability to obtain and protect intellectual property rights for our
products, dependence on collaborative relationships, the effect
of competitive
products, industry trends and other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.
He often deals with insurance and reinsurance claims, particularly high value
pharmaceutical and
products - liability claims, including many arbitrations raising a full range
of issues
concerning the validity and application
of insurance and reinsurance contracts, especially (but not only) the Bermuda Form.
Mr Kirby has litigated high - profile trademark cases
concerning the design
of the famous HENRY vacuum cleaner, where he protected the shape
of the cleaner stripped
of all other indicia, as well as magazine and book cases, Europe - wide
product launches for branded technology and
pharmaceutical products and globally famous copyright cases for the world's largest publisher.
It will also have competence over actions
concerning infringement and validity
of Supplementary Protection Certificates, for
pharmaceutical and plant protection
products, based on European bundle patents and unitary patents.
Represented an Indonesian listed group in a US$ 11.5 million ICC International Arbitration against a major healthcare multinational
concerning breaches
of Indonesian statutory duties in relation to an exclusive distributorship agreement for
pharmaceutical products
This blog contains the personal views
of the Blogging Team identified below (and
of any authors
of guest posts)
concerning various topics that arise in the defense
of pharmaceutical and medical device
product liability litigation.
Preparing medicines, injections, pumps and other
pharmaceutical products based on the name
of concerned patient and dosage listed as per the physician's order